Mice Without IgA Develop Twice as Many Colon Tumors

Researchers found that immunoglobulin A helps keep gut cells from dividing too quickly, and oral IgA doses eliminated the added tumor risk in the study mice.

Updated on Nov. 12, 2026 in Cancer

Mice Without IgA Develop Twice as Many Colon Tumors

Mice lacking immunoglobulin A developed more than twice as many colon tumors as usual, according to a study published in the journal Nature. Oral doses of IgA antibodies eliminated the increased tumor risk in those mice.

Why it matters

IgA deficiency affects about 1 in 500 people in the U.S. and has been linked to colorectal cancer in humans, suggesting the antibody may play a protective role against the disease.

In the Nature study, IgA-deficient mice developed more than twice as many colon tumors as normal mice, while IgA deficiency affects roughly 1 in 500 people in the U.S. Whether these mouse findings hold in people has not been established.

The players

Rockefeller University

A private research university in New York City where the study on IgA and colon tumors was conducted.

UCLA

The University of California, Los Angeles, where a former postdoctoral fellow on the research now works.

The details

IgA antibodies bind to the cells lining the gut and keep those epithelial cells from dividing too quickly. In IgA-deficient mice, signaling through the receptor DMBT1 goes unchecked, and gene expression linked to cell division shifts before tumors appear.

Timeline

  1. November 12, 2026: Nature publishes the study on IgA and suppression of tumorigenesis.

Health Landscape

The findings extend a line of gut-immunity research by pinpointing the DMBT1 receptor as a mechanism linking IgA deficiency to colon tumors. Their significance for population-level colorectal cancer prevention depends on whether the pathway holds up in human studies.

People with IgA deficiency are a small share of the population, but the study suggests they may face higher colorectal cancer risk. Any clinical change would require human trials before it reaches routine care.

The takeaway

Immune antibodies in the gut may do more than fight infection, helping regulate how cells grow and reducing tumor risk. Researchers are now looking at whether targeting this pathway could help prevent colon cancer in people.

Further reading

Explore more cancer news to see how immune-system research is shaping colorectal cancer prevention.